Bertrand Delsuc/X
Dec 26, 2024, 05:37
Bertrand Delsuc: Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody
Bertrand Delsuc, CEO and Founder at Biotellytics, shared a post on X:
“Illustration of China making variants to infinite: PD-1 x VEGF wasn’t enough so somone’s trying PD-1 x VEGF x CTLA-4.
CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody.”
More posts featuring Bertrand Delsuc.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53
Apr 1, 2025, 11:51
Apr 1, 2025, 11:42